Catalyst Pharmaceutical
CPRX
259 hedge funds and large institutions have $1.45B invested in Catalyst Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 25 closing their positions.
151% more call options, than puts
Call options by funds: $3.62M | Put options by funds: $1.44M
53% more capital invested
Capital invested by funds: $949M → $1.45B (+$504M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
5.55% more ownership
Funds ownership: 75.51% → 81.06% (+5.5%)
2% more funds holding
Funds holding: 255 → 259 (+4)
12% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 93
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$41.1M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$19.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$9.99M |
| 4 |
DM
Deerfield Management
New York
|
+$9.53M |
| 5 |
Man Group
London,
United Kingdom
|
+$8.81M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$4.88M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$4.38M |
| 4 |
TC
TwinBeech Capital
Purchase,
New York
|
-$2.5M |
| 5 |
Millennium Management
New York
|
-$2.21M |
CPRX Hedge Fund Activity: Q4 2023 in Review
259 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2023, worth a combined $1.45B — up 53% from $949M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CPRX positions and 25 closed out — a net gain of 9 holders — while 82 added to existing stakes and 93 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $41.1M. The largest seller was State Street, cutting an estimated $10.7M.
- 259 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2023, up from 255 in Q3 2023.
- Funds reported $1.45B of Catalyst Pharmaceutical stock for Q4 2023, up 53% quarter-over-quarter.
- 34 funds opened new Catalyst Pharmaceutical positions in Q4 2023 and 25 closed out, a net change of +9 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2023 was Morgan Stanley, an estimated $41.1M added.
- The largest Catalyst Pharmaceutical seller in Q4 2023 was State Street, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2023.